BioXcel Therapeutics Corp (BTAI) - מקדם חוב לטווח ארוך להון

BioXcel Therapeutics supplies psychiatric centers with tools to combat agitation, protecting its AI-driven repositioning technologies with patents. The ratio of long-term debt to equity, as tracked by GURU.Markets quotes, demonstrates financial leverage where 0.00 is the current value of the metric. The company's revenues are based on the commercialization of neurotherapy, specifically the sales of Igalmi in US clinics.

BioXcel Therapeutics innovations in AI-driven psychiatry necessitate an analysis of the long-term debt-to-equity ratio. This metric determines the degree of financial leverage by separating borrowed funds with maturities exceeding one year from shareholders' equity. The investor assesses the extent to which the issuer's net assets cover the long-term debt load. High costs associated with retaining neurobiologists and IT specialists make this balance critical. The indicator confirms the sustainability of the aggressive growth model.